| answer text |
<p>This information is not held centrally. All newborn babies are screened currently
for four serious but rare conditions, including Medium-chain acyl-CoA dehydrogenase
deficiency (MCADD). This is part of the postnatal pathway and is paid for as part
of the Maternity Pathway Payment (MPP). The cost for screening MCADD is not identified
separately within the MPP.</p><p> </p><p> </p><p> </p><p>The NHS Newborn Bloodspot
Screening Programme in England routinely offers newborn screening for phenylketonuria,
congenital hypothyroidism, sickle cell disease, cystic fibrosis and MCADD. Newborn
screening in England is offered between 5 and 8 days after the baby is born. The midwife
takes a small sample of blood droplets from the baby’s heel for testing on a blood
spot card.</p><p> </p><p> </p><p> </p><p>With early detection further diagnostic testing
and early treatment can then be provided and avoid any unnecessary wait and help improve
and prevent severe disability.</p><p> </p><p> </p><p> </p><p>The UK National Screening
Committee have recommended extending the newborn bloodspot screening programme in
2015 to include screening for maple syrup urine disease, homocystinuria, glutaric
acidaemia type 1 and isovaleric acidaemia.</p><p> </p>
|
|
